Document Detail

No adverse hemodynamic interaction between sildenafil and red wine.
MedLine Citation:
PMID:  15470336     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Our objective was to investigate the hemodynamic interaction between sildenafil and red wine. Sildenafil citrate (Viagra), a phosphodiesterase type 5 inhibitor, is an effective treatment for male erectile dysfunction that potentiates nitric oxide-mediated vasodilation. Alcohol is a commonly used recreational substance with complex vascular effects, which may, in part, be mediated by nitric oxide. Thus there is potential for an adverse hemodynamic interaction. METHODS: Eight healthy men received either 100 mg sildenafil, alcohol (750 mL red wine, 13.5% by volume), or the combination, in a 4-way, double placebo-controlled, randomized crossover study. Blood pressure, heart rate, and cardiac index were measured every 15 minutes up to 180 minutes. RESULTS: Results are expressed as mean +/- SEM. Red wine increased cardiac index (by 15% +/- 8%, P = .04) and heart rate (by 27% +/- 5%, P < .0001). Mean arterial pressure initially increased by approximately 5% and then fell by a maximum of approximately 7%. Sildenafil reduced peripheral vascular resistance (by 24% +/- 8%, P = .03) and mean arterial pressure (by 7% +/- 3%, P = .03) with no effect on cardiac index or heart rate. CONCLUSIONS: There is no clinically important hemodynamic interaction between sildenafil and alcohol (red wine).
Stephen J Leslie; Graham Atkins; James J Oliver; David J Webb
Related Documents :
24088716 - The role of renal denervation for the treatment of resistant hypertension.
11094866 - Pharmacokinetics and pharmacodynamic effects of nicotine nasal spray devices on cardiov...
17291656 - Nitric oxide mediates cardiovascular symptoms in alcohol withdrawal.
18094346 - Timing of blood pressure measurement related to caffeine consumption.
23553216 - Heme oxygenase inhibition increases blood pressure in pregnant rats.
16837926 - Absence of renal sequelae after childhood escherichia coli o157:h7 gastroenteritis.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  76     ISSN:  0009-9236     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-10-07     Completed Date:  2004-10-29     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  365-70     Citation Subset:  AIM; IM    
Centre for Cardiovascular Science, The University of Edinburgh, Western General Hospital, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cross-Over Studies
Double-Blind Method
Drug Interactions
Hemodynamics / drug effects
Phosphodiesterase Inhibitors / adverse effects,  pharmacology*
Piperazines / adverse effects,  pharmacology*
Reg. No./Substance:
0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Purines; 0/Sulfones; 139755-83-2/sildenafil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  QT interval prolongation after oxytocin bolus during surgical induced abortion.
Next Document:  Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure.